afabicin

antibiotic which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant Staphylococcus aureus

Also Known As:

(6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxo-1-propen-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-; AFN-1720; Debio 1450; Debio1450

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - afabicin: 2
    - Naphthyridines: 2
      - afabicin: 2

Experts

1.	Leylavergne, François: 2 articles (01/2020 - 01/2019)
2.	Overcash, J Scott: 2 articles (01/2020 - 01/2019)
3.	Wittke, Frederick: 2 articles (01/2020 - 01/2019)
4.	Chen, James: 1 article (01/2020)
5.	Dieppois, Guennaëlle: 1 article (01/2020)
6.	Heller, Barry: 1 article (01/2020)
7.	Kabler, Heidi: 1 article (01/2020)
8.	Vincent, Catherine: 1 article (01/2020)
9.	Haouala, Amina: 1 article (01/2019)
10.	Janin, Annick: 1 article (01/2019)

Related Diseases

1.	Infections 01/01/2019 - "These findings, along with preclinical efficacy data, clinical efficacy data for skin and soft tissue staphylococcal infection, the availability of both intravenous and oral formulations, and potential advantages over broad-spectrum antibiotics for the treatment of staphylococcal bone or joint infections, support the clinical development of afabicin for bone and joint infections. " 01/01/2020 - "Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid." 01/01/2019 - "Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono (Debio 1452, AFN-1252), a novel antibiotic in development which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant Staphylococcus aureus As part of clinical development in bone and joint infections, a distribution study in bone was performed in 17 patients who underwent elective hip replacement surgery. " 01/01/2020 - "Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp. The efficacy, safety, and tolerability of afabicin were compared with those of vancomycin/linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to staphylococci in this multicenter, parallel-group, double-blind, and double-dummy phase 2 study. "
2.	Staphylococcal Infections 01/01/2020 - "Afabicin was efficacious and well tolerated in the treatment of ABSSSI due to staphylococci, and these data support further development of afabicin for the treatment of ABSSSI and potentially other types of staphylococcal infections. " 01/01/2019 - "These findings, along with preclinical efficacy data, clinical efficacy data for skin and soft tissue staphylococcal infection, the availability of both intravenous and oral formulations, and potential advantages over broad-spectrum antibiotics for the treatment of staphylococcal bone or joint infections, support the clinical development of afabicin for bone and joint infections. "
3.	Nausea 01/01/2020 - "Most common treatment-emergent adverse events were mild and were headache (9.1% and 16.8%) and nausea (6.4% and 8.4%) with LD and HD afabicin, respectively. "
4.	Headache (Headaches) 01/01/2020 - "Most common treatment-emergent adverse events were mild and were headache (9.1% and 16.8%) and nausea (6.4% and 8.4%) with LD and HD afabicin, respectively. "

Related Drugs and Biologics

1.	afabicin
2.	Prodrugs
3.	Oxidoreductases (Dehydrogenase)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Acyl Carrier Protein
6.	Vancomycin
7.	Fatty Acids (Saturated Fatty Acids)
8.	Linezolid (Zyvox)
9.	API 1252